Today, Hims & Hers Health 
HIMS plunged by –28%, breaking key support around $46.
The sell-off was triggered by news that Novo Nordisk terminated its partnership with HIMS over the promotion of compounded alternatives to Wegovy, calling it “unethical.”
🔍 Key Drivers of the Drop:
• Public fallout with Novo Nordisk
• Very high trading volume (87M+) – panic selling
• RSI and Stochastic both entered oversold zones
• Key technical support at $46 was lost
🧠 Is this already priced in?
Despite the controversy, HIMS remains a strong player in telehealth and personalized treatments.
Their model isn’t solely dependent on this partnership. Investors may be overreacting.
📌 Idea: Rebound from panic-driven drop
• Entry zone: $45–46
• Target 1: $55
• Target 2: $65 (retest previous highs)
• Stop loss: $40
💬 Watch for official statements from HIMS and updates on new partnerships.
HIMS plunged by –28%, breaking key support around $46.The sell-off was triggered by news that Novo Nordisk terminated its partnership with HIMS over the promotion of compounded alternatives to Wegovy, calling it “unethical.”
🔍 Key Drivers of the Drop:
• Public fallout with Novo Nordisk
• Very high trading volume (87M+) – panic selling
• RSI and Stochastic both entered oversold zones
• Key technical support at $46 was lost
🧠 Is this already priced in?
Despite the controversy, HIMS remains a strong player in telehealth and personalized treatments.
Their model isn’t solely dependent on this partnership. Investors may be overreacting.
📌 Idea: Rebound from panic-driven drop
• Entry zone: $45–46
• Target 1: $55
• Target 2: $65 (retest previous highs)
• Stop loss: $40
💬 Watch for official statements from HIMS and updates on new partnerships.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.